Eyedeal Successfully Holds Clinical Trial Summary Meeting for the World’s New-Generation Cross-Linked polyisobutylene Intraocular Lens (IOL)

On December 15, 2023, Eyedeal successfully held the Clinical Trial Summary Meeting for its new-generation cross-linked polyisobutylene intraocular lens. Experts and professors from clinical centers across the country gathered in Xi’an, China, to review the clinical trial outcomes and share their research insights.

Professor Yune Zhao , Vice President of the Eye Hospital of Wenzhou Medical University, presented the clinical trial results at the meeting.

Led by the Eye Hospital of Wenzhou Medical University, and jointly conducted by Xi’an People’s Hospital (Xi’an Fourth Hospital), the Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine, Shantou University–The Chinese University of Hong Kong Joint Shantou International Eye Center, and Xiangya Hospital of Central South University, this domestic multi-center clinical study on the “cross-linked polyisobutylene aspheric intraocular lens” confirmed that Xi’an Eyedeal’s IOL demonstrates outstanding safety, efficacy, and overall performance. The results have been scientifically validated and support its clinical adoption.

Professor Hongsheng Bi, President of the Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine

Professor Xiaobo Xia, Vice President of Xiangya Hospital of Central South University

Professor Bo Ma, Vice President of Xi’an People’s Hospital (Xi’an Fourth Hospital) and Shaanxi Eye Hospital

During the clinical application exchange session, attending experts reviewed patient recruitment, surgical procedures, postoperative follow-up, and visual outcome evaluations at their respective centers. They shared their research experiences and expressed high expectations for the clinical prospects of cross-linked polyisobutylene IOLs, recognizing their potential to advance the industry and drive technological innovation.

The cross-linked polyolefin aspheric intraocular lens, developed using Eyedeal’s globally patented material “cross-linked polyisobutylene (xPIB),” is the first new-material IOL in nearly 30 years worldwide to enter clinical application. The successful completion of this multi-center clinical trial in China marks another solid step toward the market launch of the xPIB intraocular lens.